Ai Mediq S.A. is a Luxembourg MedTech company (est. 2010) focused on rehabilitation technologies. Ai Mediq has developed a new treatment method using personalised hypoxic load dosing: the Intermittent Hypoxic-Hyperoxic Treatment (IHHT®). The IHHT® therapy optimises the positive effects of controlled short-term hypoxic and hyperoxic exposures. Its efficacy and safety has been confirmed by extensive clinical data, paving the way for its systemic use in clinical practice. Over a decade, Ai Mediq translated the IHHT® concept into ReOxy®, a CE-marked Class IIb medical device for supervised cardiac rehabilitation in CAD patients. ReOxy® delivers automated, individualised IHHT® using continuous ICU-grade monitoring and automated treatment parameters control (SRT® technology). The device complies with MDR (EU 2017/745), ISO 13485 and IEC 60601, supporting use in high-responsibility clinical environments.